

## TMC Pharma Services Receives Investment by LDC

### Torreya advised TMC on the transaction

Hampshire and London, United Kingdom, August 24, 2022

TMC Pharma Services ("TMC") has received a £18 million minority investment by a LDC, a leading mid-market private equity firm.

TMC is a global pharmaceutical development organization that specializes in innovative treatments for rare diseases and oncology. TMC has successfully supported over 150 Orphan Drug Designations over the past 10 years in the USA, EU, Japan and Australia. The business provides a full range of expert pharma and biotech support services, from preclinical to post-marketing, for human medicines and devices. TMC's senior team, based in the UK, is supported by a worldwide network of over 900 contracted Associates, who are hand-picked to match the exact needs of each individual project. TMC's network of Associates includes some of the very best subject-matter experts in medicinal product development.

Established in 2001, TMC operates globally across four offices and hubs in the UK, Ireland, Japan and the US. The business has more than doubled its revenues over the past five years to £11.8m in 2021.

LDC is backing the existing management team, led by Co-Founder and CEO Julie Matthews and COO Carol Woodward. Its minority investment will help TMC to further expand into the US and Asia markets. The business also plans to double the number of full-time employees it has over the next five years and open new offices in key international markets.

Torreya advised TMC on this transaction, the 8th transaction announced on behalf of a pharmaceutical services company in the last year. It further highlights Torreya's increasing presence in mid-market outsourced pharma services sell-side transactions.

### ABOUT TMC PHARMA SERVICES:

For more information about TMC, please see: [www.tmcpharma.com](http://www.tmcpharma.com)

### ABOUT LDC:

For more information about LDC, please see: [www.ldc.co.uk](http://www.ldc.co.uk)

### Deal Press Release

#### Torreya Contacts

**ALAN SELBY**

Managing Director | London Office

[alan.selby@torreya.com](mailto:alan.selby@torreya.com) | +44 (0) 207-451-4553 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.